Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05721326 · ClinicalTrials.gov registry record · NA
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- NA
- Development phase
- 1,283
- Enrollment target
NCT05721326 is a NA study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 1,283 participants.
The verdict
NCT05721326, a NA study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,283 participants
- Enrollment target
Study Summary
The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and counseling that may initiate life-saving screenings.
Interventions
- OTHER Sequential EHR Communications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,283 participants |
| Start Date | 2023-05-01 |
| Est. Completion | 2025-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05721326
The ClinicalTrials.gov registry entry for NCT05721326 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,283 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sequential EHR Communications is the first listed.
NCT05721326 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05721326 about?
NCT05721326 is a clinical study titled "Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition". The goal of this sequential study design is to increase genetic testing in those meeting national clinical guidelines. The main question it aims to answer is: which intervention is most effective in uptake of genetic testing for the target population? Participants will receive genetic testing and co...
What is the current status of trial NCT05721326?
This trial is currently completed. It is a NA study. The enrollment target is 1,283 participants. The study started on 2023-05-01. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT05721326?
The interventions under investigation include: Sequential EHR Communications (OTHER).
Who is sponsoring clinical trial NCT05721326?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.